Details of the Drug Combination

General Information of Drug Combination (ID: DCJXZE3)

Drug Combination Name

Nelarabine Motixafortide

Indication

Disease Entry	Status	REF
T-Acute Lymphoblastic Leukemia	Phase 2	[1]

Component Drugs

Nelarabine DMB6VEG

Motixafortide DMW34B1

Small molecular drug

Peptide

2D MOL

3D MOL

3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Nelarabine

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Approved	[2]
T-cell acute lymphoblastic leukaemia	2A90.5	Approved	[3]
T-lymphoblastic lymphoma	N.A.	Approved	[3]

Nelarabine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA synthesis (DNA synth)	TTUBNVO	NOUNIPROTAC	Binder	[7]
------------------------------------------------------------------------------------

Nelarabine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Adenosine aminohydrolase (ADA)	DEDQHBV	ADA_HUMAN	Metabolism	[8]
------------------------------------------------------------------------------------

Indication(s) of Motixafortide

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[4]
Acute myeloid leukaemia	2A60	Phase 2	[5]
Myelodysplastic syndrome	2A37	Phase 2	[6]
Pancreatic cancer	2C10	Phase 2	[6]

Motixafortide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
C-X-C chemokine receptor type 4 (CXCR4)	TTBID49	CXCR4_HUMAN	Antagonist	[9]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02763384) BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7090).
3	Nelarabine FDA Label
4	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
5	ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Nelarabine. Drugs. 2008;68(4):439-47.
8	Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28.
9	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).